Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2003, for eXegenics Inc. (Note: The input metadata referenced "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company historically operated as a drug discovery firm but shifted strategy in 2002 to focus on clinical drug development and in-licensing. During the reporting period, the company terminated all internal research programs to pursue a strategy of acquiring niche products or entering business combinations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 | Balance Sheet (Sep 30, 2003) |
|---|---|---|---|
| Revenue | $0 | $13,000 | N/A |
| Net Loss (Attributable to Common) | $(1,525,000) | $(4,338,000) | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.28) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $11,048,000 |
| Total Assets | N/A | N/A | $12,470,000 |
| Total Liabilities | N/A | N/A | $684,000 |
| Stockholders' Equity | N/A | N/A | $11,786,000 |
| Net Cash Used in Operating Activities | N/A | $(5,039,000) | N/A |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Collapse: Revenue for the nine months ended September 30, 2003, was $13,000, a 98% decrease from $556,000 in the prior year period. The three-month period saw zero revenue.
- Expense Reduction: Research and Development (R&D) expenses dropped 95% year-over-year for the nine-month period ($154,000 vs. $3,301,000) due to the termination of all research programs. General and Administrative (G&A) expenses decreased 9% ($3,759,000 vs. $4,123,000).
- Strategic Redirection Costs: The company incurred net expenses of $561,000 for the nine months related to strategic redirection (severance, legal fees, and equipment write-downs), partially offset by $284,000 in reimbursements from Bristol-Myers Squibb.
- Improved Net Loss: Despite the strategic costs, the net loss attributable to common shareholders decreased 33% to $4,338,000 for the nine months, compared to $6,505,000 in the prior year, driven primarily by the cessation of R&D spending.
- Liquidity Position: Cash and cash equivalents increased from $6,138,000 at year-end 2002 to $11,048,000 at September 30, 2003, largely due to the maturity of a $10,004,000 government agency debt security in February 2003.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy
Management believes current cash reserves are sufficient to fund operations through at least September 30, 2004. The company is actively seeking business combinations or in-licensing opportunities to transition into a commercially oriented specialty drug company. No new material commitments for capital assets or intellectual property exist.
Material Risks and Contingencies
- Nasdaq Delisting Risk: The company received notification on October 20, 2003, of non-compliance with the minimum $1.00 closing bid price requirement and the requirement for three independent audit committee members. A hearing is scheduled for December 4, 2003. Failure to regain compliance could result in delisting to the OTC Bulletin Board.
- Legal Proceedings:
- Weiss Litigation: A shareholder class action alleges mismanagement, wasteful loans, and breach of fiduciary duties. The company believes the suit is without merit but cannot predict the outcome or liability.
- Landlord Dispute: The landlord of the company's Dallas facility claims approximately $135,000 in unpaid fees and taxes. A lien was filed on company property in October 2003, and the company has filed suit to declare it not in default.
- Employment Suit: A former employee filed a discrimination and conversion suit in October 2003.
- Failed M&A Activity:
- Foundation Group: An unsolicited tender offer and consent solicitation were terminated in September 2003 after less than 1% of shares were tendered.
- AVI BioPharma: A merger agreement and exchange offer were terminated by AVI on September 2, 2003.
- Auditor Resignation: Ernst & Young LLP resigned as independent auditor on September 17, 2003. The company engaged BDO Seidman, LLP as the new auditor in November 2003. No disagreements on accounting principles were reported.
Investor Verification Checklist
- Verify the status of the Nasdaq delisting hearing scheduled for December 4, 2003, and the company's plan to regain compliance with bid price and audit committee rules.
- Monitor the Weiss Litigation and the landlord dispute for potential financial liabilities or operational disruptions.
- Assess the progress of strategic redirection efforts, specifically any new in-licensing deals or merger discussions, given the lack of organic revenue.
- Review the cash burn rate relative to the $11 million cash balance to confirm the runway through September 2004 remains valid.
- Confirm the independence and qualifications of the new auditor, BDO Seidman, LLP, following the resignation of Ernst & Young.